Vildagliptin was reported to lower postprandial glucagon levels and improve hyperglycemia in T2DM patients [58], and DPP-4 inhibitors were observed to increase the abilities of alpha and beta cells to detect and respond to hypoglycemia [59]. This evidence concerns the gene GCG and type 2 diabetes mellitus.